(R)-2-hydroxy-3-(4-methoxyphenyl)propanoic acid | 1206734-18-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (R)-2-hydroxy-3-(4-methoxyphenyl)propanoic acid
• 英文别名: (2R)-2-hydroxy-3-(4-methoxyphenyl)propanoic acid
• CAS: 1206734-18-0
• 化学式: C₁₀H₁₂O₄
• 分子量: 196.203
• InChiKey: GEDLJGYFEOYKEG-SECBINFHSA-N

物化性质

• 沸点：
  372.9±27.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  乙酸乙烯酯 、 ethyl 2-hydroxy-3-(4-methoxyphenyl)propanoate 在 Pseudomonas cepacia lipase 、 sodium phosphate dibasic dodecahydrate 、 水 、 sodium chloride 、 sodium hydroxide 、 bovine α-chymotrypsin 作用下， 以 甲基叔丁基醚 为溶剂， 反应 312.0h， 生成 (R)-2-hydroxy-3-(4-methoxyphenyl)propanoic acid 、 (S)-2-acetoxy-3-(4-methoxyphenyl)propanoic acid 、 (S)-2-Hydroxy-3-(4-methoxyphenyl)propionsaeure
  参考文献：
  名称：

  Enzyme-mediated synthesis of EEHP and EMHP, useful pharmaceutical intermediates of PPAR agonists

  摘要：

  A new scaleable synthetic route to the title compounds has been developed. The reaction pathway is based on the alpha-chymotrypsin-catalysed hydrolysis of the racemic ethyl 2-ethoxy-3-(p-methoxyphenyl)propanoate or of the racemic ethyl 2-methoxy-3-(p-methoxyphenyl)propanoate to give the corresponding resolved (S)-esters with excellent ee. The acids were easily separated from the (S)-esters by a simple acid-base work-up. The overall yields of 1 and 2 were 16% and 17%, respectively. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.10.013

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP2243779A1

  公开（公告）日：2010-10-27

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is -N(R1b)-, etc.; G2 is -CO-, etc.; G3 is -C(R1c)(R1d)-, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及下式 (I) 的化合物或其药学上可接受的盐，可用作肾素抑制剂。 [其中R1a是卤素等；R1m是H等；G1是-N(R1b)-等；G2是-CO-等；G3是-C(R1c)(R1d)-等；G4是氧等；R1b是任选取代的C1-6烷基等。R3是H、任选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立地相同或不同，以及一个基团：-A-B（所述A是单键等、和所述 B 是 H 等）等；以及 n 是 1 等]。
• US8389511B2
  申请人：——

  公开号：US8389511B2

  公开（公告）日：2013-03-05
• Enzyme-mediated synthesis of EEHP and EMHP, useful pharmaceutical intermediates of PPAR agonists
  作者：Elisabetta Brenna、Claudio Fuganti、Francesco G. Gatti、Fabio Parmeggiani

  DOI：10.1016/j.tetasy.2009.10.013

  日期：2009.11

  A new scaleable synthetic route to the title compounds has been developed. The reaction pathway is based on the alpha-chymotrypsin-catalysed hydrolysis of the racemic ethyl 2-ethoxy-3-(p-methoxyphenyl)propanoate or of the racemic ethyl 2-methoxy-3-(p-methoxyphenyl)propanoate to give the corresponding resolved (S)-esters with excellent ee. The acids were easily separated from the (S)-esters by a simple acid-base work-up. The overall yields of 1 and 2 were 16% and 17%, respectively. (C) 2009 Elsevier Ltd. All rights reserved.